KOL Pulse AI· @KolPulseAI · X·· 8 小时前评分70
正文 · 原文
"I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing." @TejasPatilMD on DeLLphi-305
#ESMO26: most important trials + KOL discussions.
@stolaney1 (TALENT) @katy_beckermann (MIBC)
https://hubs.ly/Q04CdGx_0
36 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com